A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

(2022) Jennifer Hammond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

(2022) Yuto Unoh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2

(2022) Ryuta Uraki et al.   NATURE

Clinical findings, viral load, and outcomes of COVID-19: Comparison of patients with negative and positive initial chest computed tomography

(2022) Cherry Kim et al.   PLoS One

Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals

(2022) Jiwon Jung et al.   JAMA Network Open

Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters

(2022) Ryuta Uraki et al.   Nature Microbiology

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

(2022) Ryosuke Shimizu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic

(2021) Daniel P. Oran et al.   ANNALS OF INTERNAL MEDICINE

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

(2021) Jeroen J. A. van Kampen et al.   Nature Communications

Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19

(2021) Maria Dolores Folgueira et al.   CLINICAL MICROBIOLOGY AND INFECTION

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

(2021) Catherine M. Brown et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference

(2021) Jennifer L. McKimm-Breschkin et al.   ANTIVIRAL RESEARCH

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

(2021) Angélica Jayk Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

(2021) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

(2021) Anil Gupta et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

(2021) William A. Fischer et al.   Science Translational Medicine

Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals

(2021) Merlin Davies et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020

(2020) Anika Singanayagam et al.   Eurosurveillance

Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors

(2020) Jun He et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Viral dynamics in mild and severe cases of COVID-19

(2020) Yang Liu et al.   LANCET INFECTIOUS DISEASES

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

(2020) Andrew Clark et al.   Lancet Global Health